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ABSTRACT 
Herpes zoster ophthalmicus (HZO) is a clinical manifestation of the reactivation of latent varicella zoster virus (VZV) 
infection and is more common in people with diminished cell-mediated immunity. Lesions and pain correspond to the 
affected dermatomes, mostly in first or second trigeminal branch and progress from maculae, papules to vesicles and 
form pustules, and crusts. Complications are cutaneous, visceral, neurological, ocular, but the most debilitating is post-
herpetic neuralgia. Herpes zoster ophthalmicus may affect all the ophthalmic structures, but most severe eye-
threatening complications are panuveitis, acute retinal necrosis (ARN) and progressive outer retinal necrosis (PORN) as 
well. Antiviral medications remain the primary therapy, mainly useful in preventing ocular involvement when begun 
within 72 hours after the onset of the rash. Timely diagnosis and management of HZO are critical in limiting visual 
morbidity. Vaccine in adults over 60 was found to be highly effective to boost waning immunity what reduces both the 
burden of herpes zoster (HZ) disease and the incidence of post-herpetic neuralgia (PHN). 
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INTRODUCTION  
Varicella zoster virus (VZV, HHV-3) is a highly contagious 
DNA virus. The primary Infection typically occurs in 
childhood. The virus is responsible for causing two 
distinct diseases: 
Varicella (chickenpox), the primary, highly contagious, 
airborne VZV infection, leads to a lifelong latent 
contagion of a group of sensory ganglionic neurons in the 
trigeminal or dorsal root of the host (1). 
In contrast, herpes zoster (HZ; shingles) is a sporadic 
neurocutaneous disease that results from the 
reactivation of latent VZV (2). Varicella zoster virus 
infection can be reactivated either “spontaneously” or by 
specific triggers. Five genotypes of VZV with distinct 
geographical distribution have been defined using 
molecular techniques. Genotypes B and C are 
predominantly found in Europe and North America, 
whereas J, J2, and A1 are most prevalent in Africa and 
Asia (3). Different genotypes can establish latency within 
the same host, and also lead to independent reactivation 
episodes (4). 
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The incidence of HZ is about 3.0-3.5 per 1000 persons per 
year with a mean estimated lifetime attack rate of about 
30% (5). HZ is rare in young people; however, its 
incidence increases sharply after 50 years of age. It 
reaches roughly ten cases per 1000 persons by the age 
80, i.e. at least 50% of those surviving to 85 years of age 
will have had HZ (6). 
Herpes zoster is more frequent in individuals with 
impaired cell-mediated immunity (CMI) due to disease, 
drugs, or radiotherapy. The incidence of herpes zoster is 
20 to 100 times greater in HIV-positive patients, 
transplant recipients, or people with certain malignancies 
than in immunocompetent individuals (7). In the general 
population, older age is the most significant independent 
risk factor for HZ (8). Although HZ is not as contagious as 
primary varicella infection, patients can transmit VZV to 
non-immune contacts. 
 
PATHOGENESIS OF VZV INFECTIONS 
Site of entry of the varicella zoster virus is the upper 
respiratory tract. The virus proliferates in the adjacent 
pharyngeal lymphoid tissue and from there spreads to 
the skin causing varicella. It also induces lifelong 
immunity (9) and latency by evading the host immune 
system (10). Latency is a universal biological property of 
all herpes viruses. Taken together, the immune response 
to VZV infection is quite complex: 
1) After the local innate immunity barrier is overcome, 
the virus spreads in the body in the form of a cell-
associated viremia within memory T cells (11). 
2) Humoral immunity is built-up during the primary 
infection; however, diseases with defects in antibody 
synthesis are not associated with significantly increased 
HZ disease risk (9). 
3) Cell-mediated immunity (CMI) is the main component 
of host’s response to VZV infection and varicella. Also, 
the course of HZ is more severe in patients with CMI 
defects (12). 
Adequate T-cell immunity is essential for safeguarding 
latency. Chemical or physical factors, stress, insolation or 
solar radiation, malignant diseases, immunosuppressive 
treatments, or HIV infection may trigger VZV 
reactivation. 
 
CLINICAL MANIFESTATIONS AND DIAGNOSIS OF HERPES 
ZOSTER OPHTHALMICUS 
 
Periocular Skin Lesions 
Unilateral radicular pain and a vesicular rash (grouped 
vesicles on an erythematous base), usually limited to one 
or two adjacent dermatomes, are characteristic of HZ 
(13). Most frequent localizations are dermatomes T3, S3, 
and the first trigeminal branch that can be associated 
with herpes zoster ophthalmicus (HZO). Prodromal 
symptoms may precede the rash by several days. They 
include pruritus, dysesthesia, and pain. In rare instances, 
pain without eruption may develop (zoster sine herpete). 
Healing may take more than four weeks (14). 
The first and second branches of the trigeminal nerve are 
affected in about 10% to 20% of HZ episodes (15). 
Correspondingly, lesions are found on the forehead, 
scalp, and upper eyelid (first branch) or the cheek, lower 
eyelid, and upper lip (second branch; Figure 1). 
Emergence of skin lesions on the tip of the nose is a 
finding characteristic for the involvement of the nervus 
ophthalmicus ramus nasociliaris and a sign highly 
predictive of HZO (75% of patients; Hutchinson’s sign II). 
Involvement of the second (and third) branch of the 
trigeminal nerve may additionally affect the mouth and 
manifest as ipsilateral mucosal erosions (Figure 2). 
Visceral dissemination in immunocompromised patients 
affecting the lung, liver, and brain leads to a significant 
mortality rate, ranging from 5% to 15% (16). 
The spectrum of the differential diagnosis of facial HZ 
includes herpes simplex virus (HSV) infections, impetigo, 
contact dermatitis, insect bites, and drug eruptions. 
Herpes simplex is usually more restricted by its 
localization; however, more disseminated or segmental-
zosteriform variants of the HSV can be confused with HZ, 
although they never show dermatomal distribution. 
Moreover, HSV lesions are associated with varying 
recurrences patterns. 
In contact dermatitis, the typical prodromal signs of HZ 
are absent and pruritus is the predominant symptom. To 
date VZV DNA detection by polymerase chain reaction 
(PCR) is the most useful laboratory test for diagnosis 
confirmation (17). 
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Figure 1. Herpes Zoster of the second Trigeminal Branch 
The skin of the lower eyelid is affected and slight conjunctivitis is 
evident. The lesional skin is covered with a fusidic acid containing 
crème. 
 
 
 
Figure 2. Oral Herpes Zoster Lesions 
Buccal mucosal erosions in a patient with herpes zoster affecting the 
2nd trigeminal branch (same patient as in Figure 1). 
 
Ocular Involvement 
Herpes zoster with involvement of ocular structures (i.e. 
HZO) accounts for approximately 10% to 20% of HZ 
cases. 
Accumulated evidence suggests that eye involvement 
may be an independent unfavorable prognostic factor in 
patients with HZ. A population-based follow-up study 
was conducted to assess the risk of a subsequent cancer 
diagnosis. 
Table 1. Ocular Involvement 
Ocular Involvement 
Lid and Adnexa Blepharitis—secondary infection with 
Staphylococcus 
aureus 
Lid edema 
Vesicular lip eruption 
Phthisis bulbi 
Cicatricial entropion with or without trichiasis 
Cicatricial ectropion 
Chronic permanent scarring 
Canaliculitis 
Ptosis 
Dacryoadenitis 
Conjunctiva Hyperemic follicular conjunctivitis (rare) 
Papillary conjunctivitis 
Petechial hemorrhagic conjunctivitis 
Vesicular conjunctivitis 
Conjunctival edema 
Cicatricial conjunctival changes 
Cornea Acute epithelial keratitis 
Coarse punctate keratitis 
“Pseudodendritic” keratitis (“zoster dendrites”) 
Mucous plaques 
Nummular anterior stromal keratitis 
Interstitial keratitis 
Fascicular vascularizing keratitis 
Serpiginous ulceration 
Disciform keratitis 
Corneal hypesthesia or anesthesia 
Neurotrophic keratitis, with or without melting and 
perforation 
Corneal scars 
Calcific band keratopathy 
Lipid keratopathy 
Corneal edema 
Peripheral corneal ulceration 
Epithelial inclusion cysts 
Sclera and Episclera Scleritis 
Episcleritis 
Anterior Chamber Angle Trabeculitis 
Glaucoma, secondary to trabeculitis or attendant 
steroids 
Pupil Adie’s tonic pupil 
Horner’s syndrome 
Uvea Iritis 
Sectoral iris atrophy 
Iridocyclitis, occasionally “plastic” with hypopyon 
Anterior segment necrosis 
Choroiditis 
Panuveitis 
Lens Cataract, secondary to inflammation or attendant 
steroids 
Vitreous and Retina Retinitis or neuroretinitis 
Macular edema 
Retinal vasculitis ( Perivasculitis, arteritis and 
thrombophlebitis) 
Retinal detachment, exudative or rhegmatogenous 
Acute retinal necrosis (ARN) 
Progresive outer retinal necrosis (PORN) 
 
Optic Nerve Optic neuritis 
Retrobulbar neuritis 
Optic atrophy 
Papillitis and papilledema 
Neuroretinitis (papilledema and macular star) 
Extraocular Muscles Extraocular muscle palsies (ophthalmoplegia), 
myositis 
Ptosis 
Diplopia 
Exophthalmos 
Proptosis 
Orbit Orbital apex syndrome 
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During the 1-year follow-up, cancer was diagnosed in 
4.8% of the population. Thus, HZO may be a marker of a 
higher risk of cancer in the subsequent year (18). 
Likewise, HZO may represent a marker of increased risk 
of stroke during the 1-year follow-up period (19). A 
subsequent study found that patients previously infected 
with HZV have a 4.52-fold higher risk of stroke than their 
counterparts who had never been infected with HZV. 
Most cases of HZO have a prodromal period that may 
include fever, malaise, headache, and eye pain. Ocular 
involvement (Table 1) occurs in about 50% of patients 
with HZV infection.  
In Africa, HZO is very frequent and severe, and in some 
regions of Africa, HZ is a marker for HIV infection (20, 21). 
The overall visual outcome is good in HZO patients, who 
receive antiviral therapy. Hutchinson's sign and zoster 
anterior uveitis are potential predictors of visual loss. 
Therefore, in the presence of these predictors close 
monitoring is mandatory (22). 
 
Lids 
Early in the course of the disease, the eyelids become 
hyperemic and edematous. If the swelling is significant, 
ptosis may occur. Herpes zoster often results in cicatricial 
skin alterations. The skin of the eyelids is relatively thin, 
and secondary scarring may be more apparent in this 
area. Conversely, later restrictions in eyelid mobility 
through skin scarring or through a sustaining palsy of the 
orbicularis oris muscle result usually in lagophthalmos. 
Mild lagophthalmos or exposure of the cornea can be 
treated using artificial teardrops or ophthalmic ointment. 
When ocular lubrication alone is insufficient to treat the 
corneal signs and symptoms of lagophthalmos, a surgical 
treatment is needed that targets the anatomic 
abnormality causing the lagophthalmos. 
 
Conjunctiva 
Conjunctivitis from HZO infection can induce a 
pseudomembranous, membranous, or follicular 
response. The conjunctiva is hyperemic and edematous, 
often with petechial hemorrhages (23). The findings 
usually resolve within one week. Vesicles may be present 
on the bulbar or palpebral conjunctiva. Topical antibiotic 
drops may be administered to prevent a secondary 
bacterial infection. On the other hand topical steroids 
may be used in cases that significant inflammation. 
 
Cornea 
Approximately 65% of patients who develop HZO present 
with corneal involvement including punctate epithelial 
keratitis, early pseudodendrites, anterior stromal 
infiltrates, corneal mucous plaques, disciform keratitis, 
neurotrophic keratitis, or exposure keratitis (24). 
The clinical features of corneal disease represent direct 
viral insult, antigen–antibody reactions, delayed cell-
mediated hypersensitivity reactions, and neurotrophic 
damage (25). 
Early lesions are likely due to direct tissue damage 
caused by the florid viral infection. On the other hand, 
the late sequelae are probably the consequences of 
vasculitis, immune reactions to viral antigens, or delayed 
hypersensitivity reactions, or may occur secondary to 
nerve and tissue damage. Thus, HZO-induced corneal 
damage may occur in the early stages of the infection, or 
months or even years later. 
Despite appropriate medical and surgical management, 
significant ocular damage and loss of vision may result in 
addition to pain and light sensitivity. 
 
Epithelial Keratitis 
The first corneal finding, on slit lamp examination, is 
punctate epithelial keratitis (24), appearing as multiple, 
focal, swollen lesions that stain with Rose Bengal or 
fluorescein dye. These lesions probably contain live virus 
and resolve or progress to dendrite formation. Punctate 
epithelial keratitis may present during the first 2 days 
after the initial skin rash. Dendrites typically develop 
later (between the 4th and 6th day after the eruption); 
however, they can also appear many weeks later (25). 
They emerge as elevated plaques due to swollen 
epithelial cells. Herpes zoster dendrites form branching 
or “medusa-like“ patterns and have tapered ends (HSV 
dendrites have terminal bulbs). Punctate and dendritic 
lesions can induce anterior stromal corneal infiltrates 
(26, 27). 
 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2015;4(4)  
 
146 HERPES ZOSTER, EYE AND SKIN 
Stromal Keratitis—Anterior Stromal Keratitis 
This complication can affect as many as 25 to 30% of 
patients with HZO (28). Earliest findings of corneal 
stromal involvement become evident during the second 
week of the disease. The condition is characterized 
clinically by multiple fine granular infiltrates in the 
anterior corneal stroma below the epithelial layer. The 
infiltrates are thought to be the result of antigen-
antibody interactions due to viral proliferation in the 
epithelium (24, 27). Anterior stromal keratitis may have a 
prolonged and recurrent course. 
 
Stromal Keratitis—Deep Stromal Keratitis 
Deep stromal keratitis is a comparatively late 
manifestation of herpes zoster eye disease. It is relatively 
uncommon and typically develops 3 to 4 months after 
the initial acute herpes zoster episode, although it has 
been reported to develop from 1 month to many years 
later (25). Deep stromal keratitis may affect all levels of 
the stroma, or may consist of peripheral infiltrates with a 
surrounding immune ring. Corneal edema is a prominent 
feature at this stage, usually with anterior chamber 
inflammation. Without corticosteroid treatment, the 
tissue damage may progress into a destructive, chronic 
inflammatory response that results in neovascularization, 
scarring, and corneal ulceration. In addition, lipid 
deposition may occur. Use of corticosteroids is 
imperative to interrupt the underlying inflammatory 
process and prevent permanent alterations. 
The pathogenesis of stromal disease probably involves a 
delayed cell-mediated hypersensitivity reaction. 
Additionally, Reijo et al. described endotheliitis and 
subsequent endothelial cell loss associated with late 
stromal keratitis and keratouveitis (Figure 3) (29). 
Some patients may develop concurrent increased 
intraocular pressure (IOP) (20). Increased IOP associated 
with anterior segment inflammation from zoster can be 
difficult to treat and is long lasting. The use of 
prostaglandin analogs to control IOP is usually avoided as 
they may increase the intraocular inflammation. 
 
Neurotrophic Keratopathy and Neurotrophic Keratitis 
Neurotrophic keratopathy and neurotrophic keratitis are 
the result of decreased corneal sensation from VZV-
mediated destruction, which can cause susceptibility to 
mechanical trauma, decreased lacrimation, and delayed 
epithelial healing (25). Corneal thinning is a serious 
complication that may lead to corneal perforation. 
Because VZV infections affect sensory nerves, some 
patients experience a certain degree of hypoesthesia. 
Decreased corneal sensation reduces blinking resulting in 
corneal exposure and dry eye. Surprisingly, these 
patients have little or no discomfort because of their 
hypoesthesia. At this stage, sterile corneal ulcerations 
may occur, but can become superinfected and give rise 
to a secondary bacterial infection. If such ulcerations are 
left untreated, the cornea becomes progressively 
opaque, continues to thin, and eventually become 
perforated. 
 
 
Figure 3. Herpes zoster ophthalmicus  
A. keratitis (Descemet membrane folds) along with anterior 
uveitis (posterior synechiae remnants and irregular pupil) 
suggesting keratouveitis, and B. skin lesions corresponding to 
the affected dermatomes. 
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Peripheral Corneal Ulcers 
Peripheral corneal ulcers are a rare complication 
associated with VZV corneal infections. The ulcers may 
resemble Mooren’s ulcers and are typically associated 
with anterior uveitis or stromal keratitis, but regional 
exposure and neurotrophic keratitis must also be 
considered. 
 
Corneal Scars 
Corneal scarring commonly occurs after a VZV corneal 
infection. The corneal scar is either a faint stromal haze 
or an opaque lesion of the cornea along with corneal 
thinning. 
 
Sclera and Episclera 
Episcleritis and Scleritis 
Herpes zoster episcleritis is localized or diffuse. Scleritis is 
a more serious entity. Localized stromal keratitis may 
accompany both conditions. 
 
Uvea and Retina 
Uveitis 
It rarely occurs with the waning of varicella and occurs 
more frequently with ophthalmic zoster. Anterior uveitis 
is often unilateral acute hypertensive plastic or 
granulomatous, synechiae associated with sectorial iris 
atrophy (30). Bilateral involvement can also be present 
(31). 
Anterior uveitis may be associated with keratitis. The 
inflammation is usually mild and transient, but it 
frequently causes a hypertensive uveitis (elevation of 
intraocular pressure). Zoster uveitis can result in iris 
atrophy and an irregular pupil. The course of the disease 
may be prolonged, especially without the appropriate 
treatment. Herpes zoster uveitis may cause glaucoma. 
The total incidence of secondary glaucoma is 
approximately 13.1%. Most of the patients respond to 
antiviral and antiglaucomatous therapy, and 
trabeculectomy with mitomycin C is rarely performed. 
Uveitic glaucoma is a frequent complication of viral 
uveitis. 
Cataract formation is also typical in HZ uveitis. Chronic 
inflammation can lead to endothelial cell damage, 
resulting in corneal edema (Table 2). 
 
ARN and PORN Syndromes 
Herpes zoster virus is considered the cause in most cases 
of ARN (along with HSV1, and in some rare cases, with 
HSV2) and PORN syndromes. Compared with ARN, PORN 
is a more severe viral retinitis observed in 
immunocompromised persons, often in those with 
acquired immunodeficiency syndrome. 
Herpes zoster viruses can cause a broad spectrum of 
clinical manifestations ranging from severe ARN to slow-
progressing necrotizing and non-necrotizing types of 
inflammation. Concerning non-ARN variants which are 
underdiagnosed, patients could potentially benefit from 
earlier recognition and treatment (32). 
 
Table 2. Differential patterns of herpetic keratouveitis and 
herpetic anterior uveitis (HSV and VZV) Adapted from: David 
BenEzra, Shigeaki Ohno, Antonio G. Secchi, Jorge L. Alio, Martin 
Danitz Anterior segment intraocular inflammation guidelines 
(IOIS), 2000 
 
Location of 
Inflammation 
Herpetic Keratouveitis Herpetic Uveitis 
Corneal inflammation Active disciform (or stromal 
keratitis 
Rare, inactive 
Corneal hyposensitivity Frequent Rare 
Iris involvement  Uncommon Vasculitis, 
Sectoral atrophy  
Iridoplegia Uncommon Frequent 
Keratic precipitates Granulomatous or 
nongranulomatous 
Associated with keratitis 
Granulomatous 
Scattered 
Cells in anterior 
chamber 
± or + ++ or +++ 
Eye pressure Standard or high High or very high 
Unilateral* Always Always 
Course Chronic / recurrences Acute / 
recurrences 
*The activity of uveitis and keratouveitis is always unilateral but corneal 
and iris scars can infrequently be bilateral. 
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All patients with ARN have necrotic retinal lesions that 
progress quickly, whereas patients in the non-ARN group 
have necrotic retinal lesions that progress slowly. 
Necrotizing variants can be also noted as slowly 
progressing lesions. Some of the patients in the non-ARN 
group have posterior uveitis without retinal lesions; thus, 
vitritis, vasculitis, papillitis, and panuveitis are hallmarks 
of these cases (Figure 4), without any distinct features 
(32). Rapidly coalescent peripheral patches of retinal 
necrosis, occlusive vasculitis, and vitreous inflammation 
characterize ARN (Figure 5). Currently accepted 
diagnostic criteria for this condition are compiled in Table 
3. Progressive outer retinal necrosis (PORN) is a 
morphologic variant of acute necrotizing herpetic 
retinitis. PORN occurs most often in patients with 
advanced AIDS or patients who are otherwise profoundly 
immune-suppressed. 
 
 
Figure 4. Unilateral HZV panuveitis  
A. keratic precipites and B dense vitreous inflammation (B-
mode). 
 
The most common cause of PORN is VZV; HSV has also 
been isolated from PORN lesions. As with ARN, the 
retinitis also initiates with patches of outer retinal 
whitening with rapid merging. In contrast to ARN, the 
posterior pole may be recruited early, vitreous 
inflammatory cells are typically absent, and the retinal 
vessels are, at least initially, minimally affected. The 
visual prognosis is poor; in the largest series reported to 
date, 67% of patients had a final visual acuity (VA) of no 
light perception. The disease is often resistant to 
intravenous acyclovir alone. Successful management has 
been reported with a combination of systemic acyclovir 
and intraocular therapies with foscarnet and ganciclovir. 
 
Figure 5. Acute retinal necrosis due to HZV (detected by PCR in 
aqueous humor) with the characteristic confluent necrotic 
zones. 
 
 
 
Table 3. American Uveitis Society Criteria for Diagnosis of ARN 
Syndrome (33). 
One or more foci of retinal necrosis with discrete borders, located in 
the peripheral retina* 
Rapid progression in the absence of antiviral therapy 
Circumferential spread 
Occlusive vasculopathy with arteriolar involvement 
Prominent vitritis, anterior chamber inflammation 
Optic neuropathy/atrophy, scleritis, pain supportive but not required  
*Macular lesions do not exclude the diagnosis in the presence of 
peripheral retinitis. Am J Ophthamol. 1994; 117:663-667 (33) 
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Multifocal Posterior Necrotizing Retinitis 
Most patients whose eyes are affected demonstrate the 
known peripheral retinitis pattern, even though that 
pattern affects mainly the posterior pole in some 
patients. Most of those lesions are peripherally localized, 
focally distributed retinal necroses. They are usually well 
demarcated, with rapid circumferential progression and 
rare involvement of the posterior pole. Patients with the 
involvement of the posterior retina seem to have an 
unfavorable eyesight outcome during the first 2 years 
(34). The “Cox proportional hazards model” suggests a 
higher incidence of retinal detachment in patients with 
confluence of multifocal lesions of posterior necrotizing 
retinitis (34). Both conditions commonly cause retinal 
detachment. The prognosis is poor in patients with 
PORN; most patients ultimately have no light perception 
vision (35). The visual prognosis in patients with ARN is 
better, with many patients achieving a VA of 20/40 (36). 
A number of necrotizing retinopathies, including 
peripheral toxoplasma retinitis, syphilis, Behçet’s disease, 
intraocular lymphoma, and aspergillosis, simulate ARN 
(37). Since the vast majority of the patients have positive 
serologies for herpesviruses and Toxoplasma gondii, 
laboratory investigations may not be helpful in making 
proper etiological diagnoses. Aqueous humor analysis by 
PCR (38) and a Witmer-Goldmann coefficient 
determination are helpful for diagnosis and disease 
management. Bilateral involvement is observed with 
both clinical forms in about one-third of patients but may 
affect as many as 80% of patients with untreated disease 
(39). Treatment includes extended administration of 
intravenous and oral acyclovir and corticosteroids. Non-
necrotizing herpetic retinitis (non-necrotizing posterior 
uveitis) may occur in patients with herpetic infections. In 
13% of cases estimated as “idiopathic posterior uveitis”, 
PCR-based assays and local antibody analysis of aqueous 
fluid samples for herpesviruses, confirmed a viral 
etiology. Inflammation is typically bilateral, with cystoid 
macular edema (CME), simulating a birdshot-like 
retinochoroidopathy or a vascular occlusive bilateral 
retinitis. 
 
COMPLICATIONS OF HZV 
The complications of HZV can be divided into four groups 
(cutaneous, visceral, neurological, and ocular). The 
incidence of all complications increases with age (40). 
Ocular involvement was described above. Secondary 
bacterial superinfection by Staphylococcus aureus or 
Streptococcus pyogenes (Figure 6) is the most frequent 
cutaneous complication of HZV and may affect the 
development of subsequent post-herpetic neuralgia 
(PHN). PHN is defined as pain lasting after the rash has 
disappeared, usually when pain is present for 90 days 
after the onset of rash (13). Except for PHN, neurologic 
complications of HZO are rather rare and may include 
acute or chronic encephalitis, myelitis, aseptic 
meningitis, autonomic dysfunction, motor neuropathies, 
and cranial nerve palsies (41). 
 
 
Figure 6. Herpes zoster ophthalmicus with secondary bacterial 
superinfection (impetiginization). Honey-colored crusts on 
erythematous base at the sites of zoster skin lesions and 
conjunctivitis. Plentiful Staphylococcus aureus was grown from 
the lesions. 
 
About 20% of HZ patients develop PHN. Similar to the 
pain intensity during overt HZ, patients with HZ affecting 
dermatomes T3, S3, and the first trigeminus branch 
(HZO) are most prone to the subsequent development of 
PHN. Post-herpetic neuralgia may persist for a lifetime 
and has a significant effect on quality of life and use of 
the healthcare system’s resources. The risk of 
development and duration of PHN rise with age, 
particularly beyond the sixth decade (42). Herpes zoster 
ophthalmicus is established as an independent risk factor 
for PHN development (9). While the pathophysiology of 
PHN remains unclear, it likely results from VZV-related 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2015;4(4)  
 
150 HERPES ZOSTER, EYE AND SKIN 
damage of the sensory ganglion and may reflect 
continued inflammation by enhanced production of VZV 
(43). 
 
Treatment of Complications 
Herpes zoster is painful and associated with diminished 
quality of life (44). The treatment of HZV has three 
primary milestones: 
1) Treatment of the acute viral infection 
2) Treatment of the acute pain associated with HZV 
3) Prevention of PHN and other complications (45). 
Early commencement of antiviral therapy is essential 
(46). Nevertheless, current International Herpes 
Management Forum (IHMFR) Guidelines (47) 
recommend that all patients with HZO presenting within 
one week of rash onset should receive antiviral therapy 
in the doses indicated above. 
Antiviral drugs are highly effective in controlling the 
severity and duration of HZ; however, they do not 
reliably prevent the development of PHN with overall 
mild adverse effects such as headache, nausea, and 
gastrointestinal disturbance. Three oral nucleoside 
analogs are approved worldwide for the treatment of HZ. 
The older acyclovir [800 mg every 4 hours for 7 days for 
immunocompetent adults] had been the standard of care 
for treating cutaneous HZ. Famciclovir [500 mg every 8 
hours] and valacyclovir [1000 mg every 8 hours] are now 
preferred because of their superior pharmacokinetic 
characteristics and simpler dosing regimens. The 
recommended duration of treatment for 
immunocompetent adults is 7 days. Brivudin [125 mg, 
once daily p.o.] is available in some countries but its use 
is limited to immunocompetent patients because of a 
potentially fatal interaction with 5-fluorouracil (5-FU) 
(45). Guidelines suggest initiation of antiviral therapy 
within 72 hours of rash onset, although there are no data 
showing that later initiation is not helpful. 
Corticosteroids (20-60 mg/d prednisone equivalent) may 
help control pain in acute HZ. However, their random use 
is limited due the high prevalence of comorbidities, such 
as glaucoma, among individuals at risk for HZ 
development (older adults) (45). Individualized analgesic 
treatment schedules according to pain severity are 
preferred, and include tricyclic antidepressants, 
gabapentin, pregabalin, opioids, topical lidocaine, or 
combinations of these medications. For World Health 
Organization (WHO) grade 1 pain, treatment with 
nonsteroidal antiphlogistics is preferred (paracetamol 3-4 
x 500 mg/d p.o.; indomethacin 50-150 mg/d; ibuprofen 2 
x 800 mg/d p.o.; acetylsalicylic acid 3-4 x 0.5-1 g/d p.o.; 
naproxen 2 x 500 mg/d p.o.). Patients with WHO grade 2 
pain, which is common in HZO, may require low-potency 
opioids such as tramadol (2-3 x 50-100 mg/d) alone or in 
combination with amitriptyline (20-50 mg/d p.o.), 
gabapentin (900-2400 mg/d), or clonazepam (1.0-2.0 
mg/d). α2δ ligands such as gabapentin and pregabalin 
have been proven to effectively control PHN and improve 
the quality of life in large placebo-controlled trials (45). 
Finally, for patients presenting with WHO grade 3 pain, 
high-potency opioids such as morphine or fentanyl with 
individualized dosing regimens are recommended in 
conjunction with “co-analgesics” as required.  
Treatment of PHN is imperative, especially for elderly 
patients with HZO. These elderly patients are highly 
sensitive to short periods of compromised health, which 
can have a long-term impact on daily activities (48). 
Antiviral treatment of acute HZ and the use of systemic 
corticosteroids to diminish the degree of PHN are usually 
sufficient. It is worth noting that various treatment 
strategies are offered without adequate consensus about 
their effectiveness (49). However, recent meta-analyses 
found insufficient evidence to generally recommend 
these practices for all PHN patients (50,51).  
Finally, HZ in pregnancy is an alarming, but not 
detrimental, event. If indicated, intravenous acyclovir can 
be given. Except in cases of generalized HZ, no 
substantial viremia occurs and there are no additional 
risks for the mother or child. 
 
TREATMENT OF HZO 
The general framework of therapeutic measures for HZ 
also applies in the case of HZO. Patients with 
uncomplicated HZO can be adequately treated with oral 
acyclovir (800 mg, five to six times daily) for 7 to 10 days. 
Studies report alleviation of pain with oral acyclovir 
during the initial stages of the disease. This effect is 
especially notable if the treatment is initiated within the 
first 3 symptomatic days, and it may have a favorable 
effect even though this effect on PHN is controversial 
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(52-54). Additionally, acyclovir administration in first 72 
hours accelerates the resolution of skin lesions and 
decreases the incidence of dendritic and stromal keratitis 
as well as anterior uveitis (55,56). Valacyclovir has higher 
bioavailability and has been shown to be equally safe and 
effective for the treatment of HZ at a dosage of 3000 mg 
per day (57); if administered on a 7-day schedule, it 
prevents ocular complications of HZO (58). Famciclovir, 
500 mg orally three times a day for 7 days, may also be 
used (59). Intravenous acyclovir is recommended in 
immunocompromised patients and in immunocompetent 
with ARN or severe non-necrotizing posterior uveitis or 
panuveitis. (60,61). 
 
Table 4. Schematically overviewed HZ treatment 
Disorder Treatment 
Blepharitis/conjunctivitis Palliative care with cold compresses, 
topical lubrication and a topical broad 
spectrum antibiotic for the prevention of 
secondary bacterial infections (usually 
Staphylococcus aureus and secondarily 
Streptococcus pyogenes) 
Epithelial keratitis Debridement (optional) and topical 
lubrication 
Stromal keratitis Topical steroids/ The beneficial effect of 
topical acyclovir is unproven 
Neurotrophic keratitis Topical lubrication, topical antibiotics for 
secondary infections, tissue adhesives and 
protective contact lenses to prevent 
corneal perforation and topical or oral 
steroids to alleviate inflammation 
Scleritis/episcleritis Topical nonsteroidal anti-inflammatory 
agents and/or steroids along with topical 
and oral acyclovir for a long-term period 
(especially for scleritis) 
Uveitis Oral acyclovir for at least six months 
(usually for a year) and topical steroids in 
tapering doses 
ARN/ PORN Intravenous acyclovir (1,500 mg per m2 
per day divided into three doses) for 10 to 
21 days, followed by oral acyclovir (800 
mg orally three to five times daily) for 14 
weeks or more 
 
Patients with severe and progressive disease despite 
acyclovir therapy may be treated with ganciclovir or 
foscarnet. Intravitreal injections of 2 mg/0.1 ml 
ganciclovir may be useful as adjunctive therapy. 
In immunocompetent patients with ARN oral steroids 
administered in tapering doses (based on the amount of 
vitritis) after the patient has received intravenous 
acyclovir for 48 hours could be helpful in terms of 
reduction of inflammation. 
Laser/surgical intervention may be performed as 
required. 
Surgical Treatment of HZO complications 
When ocular lubrication alone is insufficient to treat the 
corneal complications of lagophthalmos, surgical 
treatment should be planned. 
In some cases, orbicularis oculi muscle palsy can be 
corrected by mechanical means. Both surgically 
implanted springs and gold weights have been used to 
achieve eyelid closure. Elevation of the palsied lower lid 
may also be necessary to achieve adequate treatment of 
the lagophthalmos (23). Tarsorrhaphy can become an 
additional technique to correct lagophthalmos. 
Botulinum-A toxin injected into the upper eyelid 
produces temporary ptosis and protection of ocular 
surface (62). 
As the corneal epithelium deteriorates, a punctate 
keratopathy can be seen. If the epithelial breakdown 
progresses, significant corneal epithelial defects may 
occur. Corneal ulcerations develop that are sterile in 
nature but can become infected. If left untreated, the 
cornea may become opaque, continues to thin, and 
eventually may perforate. Several studies have 
questioned the use of amniotic membrane (AM) grafts 
for the treatment of severe neurotrophic corneal ulcers 
following HZO. Authors of these studies achieved rapid 
re-epithelization and healing with reduced inflammation 
(63,64). 
Small corneal perforations of up to approximately 1.5-
mm diameter can be treated emergently with off-label 
use of cyanoacrylate glue or fibrin-based tissue adhesives 
(65-67). The purpose of using these materials is to allow 
the cornea to heal the small defect. If the defect is larger 
than what can be safely treated with a tissue adhesive, a 
patch graft (conjunctival) to the cornea is needed. 
Interrupted sutures should be used to avoid total loss of 
the graft’s sutures if one single region thins and the 
sutures become loose, break, or cheese wire through the 
tissue. Single-layer and multilayer AM grafts have been 
successfully used to close corneal perforations as large as 
1.5 to 2.0 mm. These materials have been used with 
fibrin tissue adhesive to seal the defect or with sutured 
AM alone (68-70). Investigators demonstrated an 
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increased rate of corneal re-epithelization and reduced 
rate of corneal melts with AM transplants (63, 64,71). 
In peripheral corneal ulcers, a conjunctival graft can be 
used to stabilize the cornea and halt the progression of 
corneal thinning. To accomplish a successful graft, the 
surface of the ulcer must be cleaned of any necrotic 
debris and the corneal epithelium removed from the 
region of the planned conjunctival graft site. Use of an 
AM may provide protection to the conjunctival graft and 
may reduce localized inflammation and 
neovascularization. In corneal scars if the residual 
corneal thickness, posterior to the scar, is <250 μm and 
the corneal endothelium is compromised, a penetrating 
keratoplasty (PK) will be necessary. If, however, the 
corneal endothelium is normal, then a tectonic lamellar 
keratoplasty can be performed to restore corneal clarity. 
Corneal scars in the anterior half of the cornea can be 
treated by keratectomy or lamellar keratoplasty. If the 
patient develops increased IOP and anterior segment 
inflammation, uveitic cataracts and glaucoma commonly 
occur. Therefore, cataract surgery, and in some cases, 
glaucoma filtering surgery, are required. In ARN patients 
who at baseline are in a state of relative 
immunosuppression, the outcomes obtained are good, 
suggesting a role for strong immune reactions in the 
development of retinal detachment in ARN. 
A 3600 laser photocoagulation can be performed to 
“secure” the high-risk zones (the confluent areas of 
retinal necrosis in the peripheral retina). 
Rhegmatogenous retinal detachment, which has a high-
risk of occurring (43%) (72), requires vitreous surgery 
with silicone oil tamponade. Successful retinal 
reattachment can be attained, although in some cases 
silicone oil cannot be removed due to high-risk for 
recurrent detachment. Prophylactic vitreous surgery can 
also be performed (21%) in eyes with no retinal 
detachment (72). The indication for surgery in these eyes 
is an acute worsening of vitreous haze obscuring the 
view of the fundus. 
 
PREVENTION/HZ VACCINATION 
Live attenuated herpes zoster vaccine ((Zostavax®, 
Merck) can prevent herpes zoster ophthalmicus. In 
elderly immunocompetent persons, the recurrence rate 
is estimated to be less than 1% per year (73). 
The use of HZ vaccine has been reported to be safe in 
patients with a history of HZ (74). The efficacy of the 
vaccine, however, has been shown to wane over the first 
5 years after vaccination (75). It is interesting to note 
that the safety and efficacy of HZ vaccine in persons 80 
years of age or older showed no significant difference 
from that in younger individuals (76). In the shingles 
prevention study, the efficacy of HZ vaccine in preventing 
PHN did not show a reduction in persons 70 years of age 
or older (77). 
The varicella-zoster vaccine is available in a formulation 
that contains a minimum of 19,400 plaque forming units 
per dose. The vaccine was developed for the protection 
against the onset of varicella-zoster infections. 
The varicella-zoster vaccine was evaluated in a large 
efficacy study known as “the Shingles Prevention Study 
Group.”  The study admitted subjects 60 years of age or 
older with a follow-up period of 3 years post-
vaccination.(76) The study revealed that the incidence of 
herpes zoster was 51% lower in the group of patients 
who received the vaccine 5-4 cases per 1000 person-
years compared to 11.1 cases per 1000 person-years 
among the control group (p<0.001). 
Notably, the mean duration of pain among subjects who 
received the vaccine was also significantly shorter 
compared to those who received placebo. 
Other available herpes zoster vaccines, such as the 
Varivax® and the ProQuad® (both Merck) contain 
significantly lower titers of live attenuated virus and are 
not recommended for herpes zoster (and HZO) 
prophylaxis. In older individuals, these are of insufficient 
potency to elicit an increase in cell-mediated immunity, 
Antiviral Agents to Prevent Complications of HZO 
(Guidelines) 
Antiviral therapy is most beneficial in persons who 
develop ocular complications of Herpes zoster or who 
are at risk of complications from HZO, including older 
individuals and immunocompromised patients. The use 
of antiviral agents within the first 3 days after skin rash 
may decrease the severity of HZO complications. The 
most commonly used antivirals include acyclovir, 
valacyclovir, and famciclovir. Valacyclovir or famciclovir is 
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preferred over acyclovir because of the reduced 
frequency of dosing and higher serum levels. A group of 
experts developed recommendations for the 
management of HZ. Harpaz et al. reported on the 
prevention of HZ by the Advisory Committee on 
Immunization Practices (ACIP) (78). 
To prevent the HZO complications, patient is given 
acyclovir 800 mg orally five times daily. Alternative 
antivirals include valacyclovir or famciclovir to be 
administered within the first 72 hours after the skin rash 
for a period of 7 days. Valacyclovir is given at a dosage of 
1 gram orally three times daily for 7 days, while 
famciclovir is given 500 mg orally three times a day for 7 
days. Both regimens have shown reduced time to new 
skin lesions formation, decrease in the number of 
vesicles, and full crusting and cessation of pain (79). 
In immunocompromised patients or patients with severe 
neurologic complications, acyclovir 10 mg/kg i.v. should 
be given every 8 hours for 7 days. Alternatively, foscarnet 
(in cases of acyclovir-resistance) can be used in a dose of 
30 mg/kg i.v. every 8 hours until lesions are healed. 
Antiviral therapy for herpes zoster is recommended for 
all patients who are at risk of HZO, and for all 
immunocompromised patients and all patients aged >50 
years. 
Antiviral agents can help in the resolution of herpes 
zoster lesions and decrease the complications of HZO 
and the severity of PHN. Herpes zoster vaccine is 
recommended by the ACIP for persons 60 years or older 
and is used for patients with or without a history of HZ 
(78). The earlier the antiviral therapy is initiated the 
higher the likelihood of clinical response, and 
consequently, of significant modification of the severity 
of complications. It is, therefore, recommended that 
antiviral therapy be initiated within 72 hours after the 
onset of the symptoms. Nevertheless, if the patient 
presents after 3 days, antiviral agents can still be given. 
Several studies have shown that antiviral agents may 
reduce the severity and duration of pain but do not 
reliably decrease PHN risk. Chronic neuropathic pain may 
develop in spite of antiviral therapy. 
The only effective treatment for the prevention of HZ is 
the administration of the vaccine in childhood for the 
prevention of chickenpox. Antiviral therapy is given to all 
patients presenting with HZO primarily to prevent 
potential sight-threatening complications. Patients with 
uveitis should be given adjunctive therapy with 
corticosteroids. The potential for severe pain during HZO 
should not be underestimated and potent analgesics 
must be applied as needed. Finally, PHN may be severe 
and early onset of combination therapy consisting of 
antiviral agents and pain medications including, oral 
prednisone, tricyclic antidepressants, anticonvulsants, or 
lidocaine patches (5%) may influence disease severity 
and the patient’s condition. 
 
CONCLUSION 
HZO is a serious cause of morbidity and loss of vision in 
the elderly population. Herpes zoster vaccination for 
patients with or without a history of herpes zoster may 
decrease the severity and ocular complications of HZO. 
Early detection and prompt treatment of patients who 
develop HZO are mandatory to prevent the serious 
complications of this common condition. 
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